UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)

Biochemical journal, 2010-10, Vol.431 (2), p.245-255

2010

Volltextzugriff (PDF)

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Molecular cancer therapeutics, 2007-12, Vol.6 (12), p.3314-3322

2007

Volltextzugriff (PDF)

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Journal of medicinal chemistry, 2011-09, Vol.54 (18), p.6342-6363

2011

Volltextzugriff (PDF)

Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma

Future oncology (London, England), 2016-04, Vol.12 (8), p.1001-1004

2016

Volltextzugriff (PDF)

An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

Cancer research (Chicago, Ill.), 2007-05, Vol.67 (9), p.4408-4417

2007

Volltextzugriff (PDF)

Effects of p38 MAPK Inhibition on Early Stages of Diabetic Retinopathy and Sensory Nerve Function

Investigative ophthalmology & visual science, 2010-04, Vol.51 (4), p.2158-2164

2010

Volltextzugriff (PDF)

Identification of a Structural Determinant Necessary for the Localization and Function of Estrogen Receptor α at the Plasma Membrane

Molecular and Cellular Biology, 2003-03, Vol.23 (5), p.1633-1646

2003

Volltextzugriff (PDF)

Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays

Analytical biochemistry, 2011-07, Vol.414 (2), p.179-186

2011

Volltextzugriff (PDF)

Targeting the unactivated conformations of protein kinases for small molecule drug discovery

Expert opinion on drug discovery, 2008-06, Vol.3 (6), p.595-605

2008

Volltextzugriff (PDF)

Sa1766 CB-01-35: A RIFAMYCIN IN SITU GEL ENEMA THAT DEMONSTRATES SUPERIOR EFFICACY COMPARED TO MESALAMINE AND DEXAMETHASONE IN A RAT OXAZOLONE MODEL OF ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-422-S-422

2023

Volltextzugriff (PDF)

Sa1765 CB-01-25: A RIFAMYCIN IN SITU GEL ENEMA FORMULATION FOR THE TREATMENT OF POUCHITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-422-S-422

2023

Volltextzugriff (PDF)

Tu1744 - Ex Vivo Effects of Ror-Gamma T Inhibitors on Proinflammatory Cytokine Secretion from Colonic Strips of Mice with DSS-Induced Colitis

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1007-S-1008

2018

Volltextzugriff (PDF)

Catalytic Mechanism of the Quinoenzyme Amine Oxidase from Escherichia coli: Exploring the Reductive Half-Reaction

Biochemistry (Easton), 1997-02, Vol.36 (7), p.1608-1620

1997

Volltextzugriff (PDF)

Abstract 1174: CT179 degrades the olig2 transcription factor in glioblastoma stem-like cells and prolongs survival

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1174-1174

2017

Volltextzugriff (PDF)

VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease

Inflammopharmacology, 2020-04, Vol.28 (2), p.499-511

2020

Volltextzugriff (PDF)

DDIS-19. CT-179: AN INHIBITOR OF THE OLIG2 TRANSCRIPTION FACTOR WITH POTENT ANTI-TUMOUR ACTIVITY IN BRAIN CANCER

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi73-vi73

2018

Volltextzugriff (PDF)

107 - A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S30-S31

2017

Volltextzugriff (PDF)

A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S30-S31

2017

Volltextzugriff (PDF)

Abstract 3030: CT179: A novel small molecule Olig2 inhibitor for the treatment of glioblastoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3030-3030

2016

Volltextzugriff (PDF)

Abstract 2180: Drug-like inhibitors of SGK1: Discovery and optimization of low molecular weight fragment leads

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2180-2180

2016

Volltextzugriff (PDF)

EXTH-18. CT-179 SELECTIVELY TARGETS OLIG2-POSITIVE GLIOMA STEM CELLS AND DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi76-vi76

2017

Volltextzugriff (PDF)

Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-320-LB-320

2019

Volltextzugriff (PDF)

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

Biochemistry (Easton), 2009-06, Vol.48 (23), p.5339-5349

2009

Volltextzugriff (PDF)

Molecular cloning, gene organization, and expression of mouse Mpi encoding phosphomannose isomerase

Glycobiology (Oxford), 2002-07, Vol.12 (7), p.435-442

2002

Volltextzugriff (PDF)

HGG-01. RADIATION INCREASES PRE-CLINICAL EFFICACY OF OLIG2 INHIBITOR CT-179 IN PEDIATRIC GBM

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i89-i89

2018

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(104)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(48)
Humans
(39)
Animals
(28)
Biochemistry & Molecular Biology
(19)
Biological And Medical Sciences
(15)
Female
(15)
Male
(11)
Mice
(11)
Medical Sciences
(10)
Kinetics
(9)
Molecular Sequence Data
(9)
Protein Kinase Inhibitors - Pharmacology
(8)
Fundamental And Applied Biological Sciences. Psychology
(7)
Medicine, Research & Experimental
(7)
Pharmacology & Pharmacy
(7)
Research & Experimental Medicine
(7)
Sheep
(7)
Carbohydrate Sequence
(6)
Chemistry
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma

An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

Effects of p38 MAPK Inhibition on Early Stages of Diabetic Retinopathy and Sensory Nerve Function

Identification of a Structural Determinant Necessary for the Localization and Function of Estrogen Receptor α at the Plasma Membrane

Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays

Targeting the unactivated conformations of protein kinases for small molecule drug discovery

Sa1766 CB-01-35: A RIFAMYCIN IN SITU GEL ENEMA THAT DEMONSTRATES SUPERIOR EFFICACY COMPARED TO MESALAMINE AND DEXAMETHASONE IN A RAT OXAZOLONE MODEL OF ULCERATIVE COLITIS

Sa1765 CB-01-25: A RIFAMYCIN IN SITU GEL ENEMA FORMULATION FOR THE TREATMENT OF POUCHITIS

Tu1744 - Ex Vivo Effects of Ror-Gamma T Inhibitors on Proinflammatory Cytokine Secretion from Colonic Strips of Mice with DSS-Induced Colitis

Catalytic Mechanism of the Quinoenzyme Amine Oxidase from Escherichia coli: Exploring the Reductive Half-Reaction

Abstract 1174: CT179 degrades the olig2 transcription factor in glioblastoma stem-like cells and prolongs survival

VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease

DDIS-19. CT-179: AN INHIBITOR OF THE OLIG2 TRANSCRIPTION FACTOR WITH POTENT ANTI-TUMOUR ACTIVITY IN BRAIN CANCER

107 - A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

A Novel ROR-Gamma T Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

Abstract 3030: CT179: A novel small molecule Olig2 inhibitor for the treatment of glioblastoma

Abstract 2180: Drug-like inhibitors of SGK1: Discovery and optimization of low molecular weight fragment leads

EXTH-18. CT-179 SELECTIVELY TARGETS OLIG2-POSITIVE GLIOMA STEM CELLS AND DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA

Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

Molecular cloning, gene organization, and expression of mouse Mpi encoding phosphomannose isomerase

HGG-01. RADIATION INCREASES PRE-CLINICAL EFFICACY OF OLIG2 INHIBITOR CT-179 IN PEDIATRIC GBM

Suchergebnisse filtern